Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

Author de Camargo, Tarsila Mendes Google Scholar
de Freitas, Elisangela Oliveira Google Scholar
Gimenez, Alba Marina Autor UNIFESP Google Scholar
Lima, Luciana Chagas Google Scholar
Caramico, Karina de Almeida Google Scholar
Francoso, Katia Sanches Google Scholar
Bruna-Romero, Oscar Google Scholar
Andolina, Chiara Google Scholar
Nosten, Francois Google Scholar
Renia, Laurent Google Scholar
Ertl, Hildegund C. J. Google Scholar
Nussenzweig, Ruth S. Google Scholar
Nussenzweig, Victor Google Scholar
Rodrigues, Mauricio M. Autor UNIFESP Google Scholar
Reyes-Sandoval, Arturo Google Scholar
Soares, Irene S. Google Scholar
Abstract Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-All(FL)) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-All(CT)) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against P. vivax malaria.
xmlui.dri2xhtml.METS-1.0.item-coverage London
Language English
Sponsor Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV)
FAPESP fellowships
CNPq
CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) fellowship
Medical Research Council, MRC
Wellcome Trust
Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme - Wellcome Trust
Singapore Immunology Network (SIgN)
Horizontal Programme on Infectious Diseases under Agency for Science, Technology and Research (A*STAR, Singapore)
Grant number FAPESP: 2012/13032-5
FAPESP fellowships: 2014/18102-7, 2009/15099-7
Medical Research Council, MRC: MR/N019008/1
Wellcome Trust: 089179
Date 2018
Published in Scientific Reports. London, v. 8, p. -, 2018.
ISSN 2045-2322 (Sherpa/Romeo, impact factor)
Publisher Nature Publishing Group
Extent -
Origin http://dx.doi.org/10.1038/s41598-017-19063-6
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000422739300081
URI https://repositorio.unifesp.br/handle/11600/54260

Show full item record




File

Name: WOS000422739300081.pdf
Size: 2.893Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account